- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03614702
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
Safety and Immunogenicity Evaluation of Different Sequential Immunization Schedules of Type1+2 Bivalent Oral Poliovirus Vaccine(bOPV) Co-administered With Inactived Poliovirus Vaccine(IPV) in Infants Aged 2 Months: a Randomized, Double Blind, Single Center, Parallel Trial
With the progress of the eradication of polio, bivalent oral attenuated live poliomyelitis vaccine against type 1 and 3 (bOPV) and inactivated poliomyelitis vaccine made by Sabin strain (sIPV) are required to use in the "Strategy of Polio Eradication & Endgame Strategic Plan 2013-2018" worldwide.
To evaluate the safety and immunogenicity by different sequential schedules of bOPV/tOPV with IPV(sIPV/cIPV), a randomized, double blind, single center and parallel phase Ⅲ clinic trial was performed in Infants of two-month-old in Guangxi Province, China.
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: 1-dose cIPV + 2-doses bOPV (Candy)
- Biological: 1-dose sIPV + 2-doses bOPV (Candy)
- Biological: 2-doses cIPV + 1-dose bOPV (Candy)
- Biological: 2-doses sIPV + 1-dose bOPV (Candy)
- Biological: 2-doses cIPV + 1-dose tOPV (Candy)
- Biological: 2-doses sIPV + 1-dose tOPV (Candy)
- Biological: 1-dose cIPV + 2-doses bOPV (Liquid)
- Biological: 1-dose sIPV + 2-doses bOPV (Liquid)
- Biological: 2-doses cIPV + 1-dose bOPV (Liquid)
- Biological: 2-doses sIPV + 1-dose bOPV (Liquid)
- Biological: 2-doses cIPV + 1-dose tOPV (Liquid)
- Biological: 2-doses sIPV + 1-dose tOPV (Liquid)
Detailed Description
According to the requirement of the Strategy of Polio Eradication & Endgame Strategic Plan 2013-2018, bivalent oral attenuated live poliomyelitis vaccine against type 1 and 3 (bOPV) and inactivated poliomyelitis vaccine made by Sabin strain (sIPV) need to be used to eradiation both the wild poliovirus and vaccine-derived poliovirus.
By studying different sequential immunization schedules of bOPV(candy/liquid) with IPV(cIPV/sIPV) to evaluate the safety and immunogenicity of bivalent oral poliomyelitis vaccine co-administered with IPV in healthy Infants. A randomized, double blind, single center and parallel phase Ⅲ clinic trial was performed in Guangxi Province in China. A total of 1200 infants at 2 months old were selected, and randomly divided into 12 different groups (100 individuals were included in each group) administrated the vaccines at 0, 28, 56 days schedule. The bOPV(bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3), tOPV(trivalent OPV against type 1, type 2 and type 3), sIPV (Inactivated Poliomyelitis Vaccine Made from Sabin Strains)and conventional IPV (Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains) were assign to different group of sequential immunization schedules.
The detail of each group as following:
1)1-dose cIPV + 2-doses bOPV (Candy); 2)1-dose sIPV + 2-doses bOPV (Candy); 3)2-doses cIPV + 1-dose bOPV (Candy); 4)2-doses sIPV + 1-dose bOPV (Candy); 5)2-doses cIPV + 1-dose tOPV (Candy); 6)2-doses sIPV + 1-dose tOPV (Candy); 7)1-dose cIPV + 2-doses bOPV (Liquid); 8)1-dose sIPV + 2-doses bOPV (Liquid); 9)2-doses cIPV + 1-dose bOPV (Liquid); 10)2-doses sIPV + 1-dose bOPV (Liquid); 11)2-doses cIPV + 1-dose tOPV (Liquid); 12)2-doses sIPV + 1-dose tOPV (Liquid).
Blood Sample was collected before vaccination and 28 days after the third dose of vaccination. Neutralization antibody against type I, Type I and Type III poliomyelitis virus were detected to evaluate the seroprotection rates and antibody geometric mean concentrations. The safety of different sequential schedule immunization for the vaccines also been monitored.
The first 10% of subjects in each research site,fecal samples were collected to test polio virus shedding.The 7 times are before the second dose immunization and the 7、14、28 days after the second and the third dose immunization.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China, 530028
- Guangxi Provincial Center for Diseases Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Term pregnancy (37-42 weeks), birth weight meets the standards (over 2500g), aged from 60 days to 90 days old;
- parent(s) or guardians are able to understand and sign informed consent for participation;
- Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;
- subject didn't administrate with any immunoglobulin after birth (except the Hepatitis B specific immunoglobulin) and did not administrate any other live vaccines within 28 days or inactivated vaccines within 14 days;
- Axillary temperature ≤37.1℃.
Exclusion Criteria:
Subjects will not be eligible for the study if any of the following criteria is met:
- Subject who has a medical histroy with Hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness
- Subject who is allergy to Streptomycin, neomycin and polymyxin B
- Subject with immunodeficency or are in the process of immunosuppressor therapy
- Clinical diagnosis of poliomyelitis;
- Acute febrile disease or infectious disease;
- Labor abnormal, asphyxiation rescues, congenital abnormality, developmental disability, serious chronic diseases;
- Allergic to any ingredient of vaccine or with allergy history to any vaccine;
- Taking orally injecting of steroid hormone over 14 days in the recent month;
- Febrile (temperature ≥ 38.0°C) in three days;
- Diarrhea with one week (more than 3 motions a day);
- Taking part in another clinical trail;
- Any OPV vaccination contraindication and any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1-dose cIPV + 2-doses bOPV (Candy)
cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 3 polio virus ≥5.3lgCCID50. |
Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 1-dose sIPV + 2-doses bOPV (Candy)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 3 polio virus ≥5.3lgCCID50. |
Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses cIPV + 1-dose bOPV (Candy)
cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 3 polio virus ≥5.3lgCCID50 |
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses sIPV + 1-dose bOPV (Candy)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 3 polio virus ≥5.3lgCCID50 |
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses cIPV + 1-dose tOPV (Candy)
cIPV: Inactivated Poliomyelitis Vaccine(Vero) Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 2 polio virus ≥4.8lgCCID50,type 3 polio virus ≥5.3lgCCID50 |
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses sIPV + 1-dose tOPV (Candy)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 2 polio virus ≥4.8lgCCID50,type 3 polio virus ≥5.3lgCCID50 |
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
|
Experimental: 1-dose cIPV + 2-doses bOPV (Liquid)
cIPV: Inactivated Poliomyelitis Vaccine(Vero) Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
Experimental: 1-dose sIPV + 2-doses bOPV (Liquid)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses cIPV + 1-dose bOPV (Liquid)
cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses sIPV + 1-dose bOPV (Liquid)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses cIPV + 1-dose tOPV (Liquid)
cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml,type1 polio virus≥ 7.0 lgCCID50/ml,type2 polio virus ≥ 6.0lgCCID50/ml,type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
Experimental: 2-doses sIPV + 1-dose tOPV (Liquid)
sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 2 polio virus ≥ 6.0lgCCID50/ml,type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person ) |
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibody titers of anti-poliovirus antibodies in serum of children who received 2 -doses cIPV/sIPV+1 dose tOPV or 2-doses cIPV/sIPV +1 dose bOPV.
Time Frame: at the 28 days after finishing the 3rd dose
|
Based on neutralization test to measure the production of serum antibody.
In order to identify what kind of immune programme for children is best.
The study will compare the antibody seroconversion rate and antibody geometric mean titers(GMTs) for Type I, Type II and Type III Poliomyelitis after sequential immunization of 2-doses cIPV/sIPV + 1-dose tOPV (Liquid / candy) with 2-doses cIPV /sIPV+ 1-dose bOPV (Liquid/ candy).
|
at the 28 days after finishing the 3rd dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety:number of adverse events and serious adverse events
Time Frame: within 28 days after each dose injection
|
Local and systemic adverse events were active collected and recorded to calculate the number of adverse events and serious adverse events when the subject received each dose of vaccine ,especially the bOPV.
|
within 28 days after each dose injection
|
Long term Safety:number of serious adverse events
Time Frame: Up to 6month after finishing the 3rd dose
|
Over a period of 6 months the study observed for the safety of each sequential immunization schedule.Serious adverse events were collected and recorded after finishing the 3rd dose.
|
Up to 6month after finishing the 3rd dose
|
Antibody titers of anti-poliovirus antibodies in serum of children who received 1 dose cIPV/sIPV+2 dose bOPV(candy/liquid) or 2 doses cIPV/sIPV+1 dose bOPV
Time Frame: at the 28 days after finishing the 3rd dose
|
Based on neutralization test to measure the production of serum antibody.
In order to identify what kind of immune programme for children is best.
The study will compare the antibody seroconversion rate and antibody geometric mean titers(GMTs) for Type I, Type II and Type III Poliomyelitis after sequential immunization .The antibody seroconversion rate and antibody geometric mean titers for type I, type II and Type III of 1-dose cIPV/sIPV + 2-doses bOPV (Liquid/ candy) with 2-doses cIPV/sIPV + 1-dose bOPV(Liquid / candy) .
|
at the 28 days after finishing the 3rd dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral shedding
Time Frame: before the second dose;the 7 days after the second dose;the 14 days after the second dose;the 28 days after the second dose;the 7 days after the third dose;the 14 days after the third dose;the 28 days after the third dose
|
The first 10% of subjects in each research site,fecal samples were collected to test poliovirus shedding. Whether the fecal sample contain polio virus or other enterovirus,using L20B cell and RD cell to solation and identification of polio virus from subjects' fecal suspension sample. PCR and serotypes are used to identify of polio virus types(type I、II、III). The WHO "polio laboratory manual" and the standard "diagnosis for poliomyelitis(WS 294-2016)" of PRC were used for method reference. |
before the second dose;the 7 days after the second dose;the 14 days after the second dose;the 28 days after the second dose;the 7 days after the third dose;the 14 days after the third dose;the 28 days after the third dose
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Zhaojun Mo, Master, Guangxi Province Center for Diseases Control and Prevention
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- bOPV-PRO-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poliomyelitis
-
Uniformed Services University of the Health SciencesUnknown
-
GlaxoSmithKlineCompletedPoliomyelitis | Poliomyelitis VaccinesChina
-
University Hospital, MontpellierCompletedPoliomyelitis SequelaeFrance
-
University Hospital, MontpellierCompletedPost-Poliomyélitis SyndromFrance
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and Prevention; Government of BangladeshNot yet recruiting
-
Institut de Sante Parasport Connecte SynergiesAssistance Publique - Hôpitaux de ParisRecruiting
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, BangladeshCompleted
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, Bangladesh; World Health... and other collaboratorsEnrolling by invitation
-
Pierre Van DammeBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PA... and other collaboratorsCompleted
-
Sinovac Biotech Co., LtdCompleted
Clinical Trials on 1-dose cIPV + 2-doses bOPV (Candy)
-
Bilthoven BiologicalsSerum Institute of India Pvt. Ltd.CompletedImmune Response to Oral Polio VaccineBangladesh
-
Rutgers, The State University of New JerseyCenters for Disease Control and PreventionCompletedViolence | Helping Behavior | Sexual Assault and Rape | Assaultive BehaviorUnited States
-
PfizerCompletedFungal InfectionNetherlands
-
University of MinnesotaRecruitingSolid Organ TransplantUnited States
-
Centre Hospitalier Universitaire de Saint EtienneSanofi Pasteur, a Sanofi Company; Bioster, a.s.Completed
-
Novartis PharmaceuticalsCompletedSchizophrenia DisordersUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | FluChina
-
Medy-ToxCompletedLateral Canthal Lines | Glabellar LinesUnited States, Russian Federation, Germany, Canada, Belgium, United Kingdom
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma